Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …

Chimeric antigen receptor T-cell (CAR-T) therapy is the result of combining genetic
engineering-based cancer immunotherapy with adoptive cell therapy (ACT). CAR-T therapy …

Chimeric antigen receptor (CAR)-T cell therapy represents a landmark advance in
personalized cancer treatment. CAR-T strategy generally engineers T cells from a specific …

Vascular endothelial growth factor-A (VEGF) is the predominant angiogenic factor that is
expressed in solid tumors. Besides its critical function in mediating tumor angiogenesis …

Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types
of hematological malignancies, but have shown limited efficacy in patients with glioblastoma …

Cell‐based immunotherapy, for example, chimeric antigen receptor T (CAR‐T) cell
immunotherapy, has revolutionized cancer treatment, particularly for blood cancers …

Adoptive T‐cell transfer (ACT) therapies, including of tumor infiltrating lymphocytes (TILs)
and T cells gene‐modified to express either a T cell receptor (TCR) or a chimeric antigen …

For successful application of chimeric antigen receptor (CAR) T cell therapy in solid tumors,
major hurdles have to be overcome. CAR T cells have to cross the vascular barrier, which is …

Adoptive T cell therapies based on chimeric antigen receptors (CAR-T) are emerging as
genuine therapeutic options for the treatment of hematological malignancies. The observed …

Background Chordomas are rare osseous neoplasms with a dismal prognosis when they
recur. Here we identified cell surface proteins that could potentially serve as novel …